Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies

Peroxisome proliferator-activated receptors (PPARs) play an important role in regulating both glucose and lipid metabolism. Agonists for both PPARγ and PPARγ have been used to treat dyslipidemia and hyperglycemia, respectively. In addition to affecting glucose metabolism, PPARγ agonists also regulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Deeg, Mark A., Tan, Meng H.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2008
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2519139/
https://www.ncbi.nlm.nih.gov/pubmed/18769492
http://dx.doi.org/10.1155/2008/520465
_version_ 1782158630652477440
author Deeg, Mark A.
Tan, Meng H.
author_facet Deeg, Mark A.
Tan, Meng H.
author_sort Deeg, Mark A.
collection PubMed
description Peroxisome proliferator-activated receptors (PPARs) play an important role in regulating both glucose and lipid metabolism. Agonists for both PPARγ and PPARγ have been used to treat dyslipidemia and hyperglycemia, respectively. In addition to affecting glucose metabolism, PPARγ agonists also regulate lipid metabolism. In this review, we will focus on the randomized clinical trials that directly compared the lipid effects of the thiazolidinedione class of PPARγ agonists, pioglitazone and rosiglitazone, head-to-head either as monotherapy or in combination with other lipid-altering or glucose-lowering agents
format Text
id pubmed-2519139
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-25191392008-08-27 Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies Deeg, Mark A. Tan, Meng H. PPAR Res Review Article Peroxisome proliferator-activated receptors (PPARs) play an important role in regulating both glucose and lipid metabolism. Agonists for both PPARγ and PPARγ have been used to treat dyslipidemia and hyperglycemia, respectively. In addition to affecting glucose metabolism, PPARγ agonists also regulate lipid metabolism. In this review, we will focus on the randomized clinical trials that directly compared the lipid effects of the thiazolidinedione class of PPARγ agonists, pioglitazone and rosiglitazone, head-to-head either as monotherapy or in combination with other lipid-altering or glucose-lowering agents Hindawi Publishing Corporation 2008 2008-08-21 /pmc/articles/PMC2519139/ /pubmed/18769492 http://dx.doi.org/10.1155/2008/520465 Text en Copyright © 2008 M. A. Deeg and M. H. Tan. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Deeg, Mark A.
Tan, Meng H.
Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
title Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
title_full Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
title_fullStr Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
title_full_unstemmed Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
title_short Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
title_sort pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2519139/
https://www.ncbi.nlm.nih.gov/pubmed/18769492
http://dx.doi.org/10.1155/2008/520465
work_keys_str_mv AT deegmarka pioglitazoneversusrosiglitazoneeffectsonlipidslipoproteinsandapolipoproteinsinheadtoheadrandomizedclinicalstudies
AT tanmengh pioglitazoneversusrosiglitazoneeffectsonlipidslipoproteinsandapolipoproteinsinheadtoheadrandomizedclinicalstudies

Ejemplares similares